{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:42:18Z","timestamp":1793220138700,"version":"4.5.0"},"reference-count":17,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Li-Fraumeni Syndrome (LFS) is defined by germline mutations of the p53 tumour suppressor gene. Adrenocortical carcinoma (ACC) is a rare aggressive malignancy that is commonly associated with LFS. Most LFS-linked ACC cases occur in children, and limited research has been dedicated to the clinical outcomes and genomics of adult cases with LFS-linked ACC. We report on a 34-year-old female who was diagnosed with three separate malignancies: stage III invasive ductal carcinoma of the right breast, metastatic ACC from the right adrenal gland, and grade 2 pleomorphic sarcoma of the left hand. Her invasive breast ductal carcinoma was treated with neoadjuvant chemotherapy, and she received a bilateral mastectomy after her LFS was confirmed with genetic blood testing. Adrenal ACC was initially treated with a right nephrectomy and adrenalectomy, followed by adjuvant mitotane and two lines of chemotherapy after disease recurrence. Her hand sarcoma was treated by second ray amputation. Further, we conducted deep next-generation sequencing of each of her unique tumour tissue samples using FoundationONE CDx. A whole-genome shot capture followed by in vitro sequencing performed by the Illumina\u00ae HiSeq platform revealed a germline P191fs*18 TP53 mutation across all three tissue samples. This case provides insight into the genomics and clinical characteristics of LFS-linked adult-onset ACC and demonstrated that p53 mutations were preserved throughout each malignancy, without apparent treatment pressures on genomic profiling. This case reinforces the critical importance of adopting best practices for LFS, which include the implementation of highly vigilant screening and management of care in a multidisciplinary setting.<\/jats:p>","DOI":"10.3390\/curroncol28010025","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T04:55:31Z","timestamp":1611032131000},"page":"226-232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report"],"prefix":"10.3390","volume":"28","author":[{"given":"Suraya","family":"Bondy","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tajzler","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien J.","family":"Hotte","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9180-8029","authenticated-orcid":false,"given":"Anil","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zbuk","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-9112","authenticated-orcid":false,"given":"Aly-Khan A.","family":"Lalani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1947601911413466","article-title":"Li-Fraumeni Syndrome","volume":"2","author":"Malkin","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_2","unstructured":"Schneider, K., Zelley, K., Nichols, K.E., and Garber, J. (2020, December 30). Li-Fraumeni Syndrome. GeneReviews, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1311\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mce.2011.09.010","article-title":"Towards an understanding of the role of p53 in adrenocortical carcinogenesis","volume":"351","author":"Wasserman","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"E476","DOI":"10.1210\/jc.2011-1982","article-title":"TP53 germline mutations in adult patients with adrenocortical carcinoma","volume":"97","author":"Herrmann","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","unstructured":"FoundationOne CDx (2019). Technical Information, Foundation Medicine. Available online: https:\/\/assets.ctfassets.net\/vhribv12lmne\/6Rt6csmCPuaguuqmgi2iY8\/2fe839f0e9075cf4a047bf241374e6af\/F1CDx.Label.Technical_Info_Final_July_2019.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Jasim","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: A clinician\u2019s update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-015-0047-3","article-title":"Programmed death ligand-1 expression in adrenocortical carcinoma: An exploratory biomarker study","volume":"3","author":"Fay","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40291-013-0020-0","article-title":"Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome: Current Status of Clinical Applications and Future Directions","volume":"17","author":"Sorrell","year":"2013","journal-title":"Mol. Diagn. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Fassnacht","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1530\/EC-18-0526","article-title":"Adrenocortical carcinoma in patients with MEN1: A kindred report and review of the literature","volume":"8","author":"Wang","year":"2019","journal-title":"Endocr. Connect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.18632\/oncotarget.22927","article-title":"Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas","volume":"9","author":"Shimura","year":"2018","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12020-017-1270-0","article-title":"Palbociclib inhibits proliferation of human adrenocortical tumor cells","volume":"59","author":"Fiorentini","year":"2018","journal-title":"Endocrine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103029","DOI":"10.1016\/j.critrevonc.2020.103029","article-title":"Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review","volume":"153","author":"Assi","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:32Z","timestamp":1760179712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["curroncol28010025"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28010025","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}